Pharmacological therapy in Brugada syndrome

Oholi Tovia Brodie, Yoav Michowitz, Bernard Belhassen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Brugada syndrome (BrS) is a cardiac disease caused by an inherited ion channelopathy associated with a propensity to develop ventricular fibrillation. Implantable cardioverter defibrillator implantation is recommended in BrS, based on the clinical presentation in the presence of diagnostic ECG criteria. Implantable cardioverter defibrillator implantation is not always indicated or sufficient in BrS, and is associated with a high device complication rate. Pharmacological therapy aimed at rebalancing the membrane action potential can prevent arrhythmogenesis in BrS. Quinidine, a class 1A antiarrhythmic drug with significant Ito blocking properties, is the most extensively used drug for the prevention of arrhythmias in BrS. The present review provides contemporary data gathered on all drugs effective in the therapy of BrS, and on ineffective or contraindicated antiarrhythmic drugs.

Original languageEnglish
Pages (from-to)135-142
Number of pages8
JournalArrhythmia and Electrophysiology Review
Issue number2
StatePublished - 1 Jun 2018


  • Arrhythmia
  • Bepridil
  • Brugada syndrome
  • Cilostazol
  • Denopamine
  • Disopyramide
  • Isoproterenol
  • Orciprenaline
  • Pharmacology
  • Quinidine
  • Quinine


Dive into the research topics of 'Pharmacological therapy in Brugada syndrome'. Together they form a unique fingerprint.

Cite this